Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21562986 | 0.90 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL23647003 | 0.84 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL21562985 | 0.79 | GAA (0.49) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL21563114 | 0.77 | HPGD (0.42) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL23646997 | 0.76 | PDK2 (0.33) | ALDH1A1GAAL3MBTL1PDK2 | |
| SCHEMBL21562984 | 0.75 | HPGD (0.41) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL21562968 | 0.75 | HPGD (0.34) | TBXAS1ALDH1A1SMN1; SMN2HPGDGAA | |
| SCHEMBL21549903 | 0.75 | HPGD (0.41) | ALDH1A1SMN1; SMN2HPGDGAATSHR | |
| SCHEMBL23646982 | 0.73 | PDK2 (0.31) | PDK2 | |
| SCHEMBL23646981 | 0.73 | PDK2 (0.31) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-22 | — | — | US | disclosed |
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-22 | — | — | US | disclosed |
| CN-112638883-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2019214610-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, TYMP, HAVCR2 | TBXAS1 623/4885ALDH1A1 1457/4885SMN1; SMN2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.